Antagonists of lysophosphatidic acid receptors

A compound having the structure of Formula (I), or a pharmaceutically acceptable salt thereof:

• wherein
• R1 is —CO2H, —CO2RD, —C(═O)NHSO2R10, —C(═O)N(R9)2, —C(═O)NH—OH, —C(═O)NH—CN, —CN, —C(═NH)—NH2, —C(═NH)—NHC(═O)RD, —C(═O)NHCH2CH2SO3H, tetrazolyl or carboxylic acid bioisostere;
• RD is H or C1-C6alkyl;
• ring A is a substituted or unsubstituted C3-C10cycloalkylene, a substituted or unsubstituted C2-C10heterocycloalkylene, a substituted or unsubstituted arylene, or a substituted or unsubstituted heteroarylene, where if ring A is substituted then ring A is substituted with 1, 2, or 3 RA;
• ring B is a substituted or unsubstituted C3-C10cycloalkylene, a substituted or unsubstituted C2-C10heterocycloalkylene, a substituted or unsubstituted arylene, or a substituted or unsubstituted heteroarylene, where if ring B is substituted then ring B is substituted with 1, 2, or 3 RB;
• L1 is absent, C1-C6alkylene, C1-C6-fluoroalkylene, or C1-C6heteroalkylene;
• L2 is absent, C1-C6alkylene, C1-C6-fluoroalkylene, C1-C6heteroalkylene, —O—, —S—, —SO—, —SO2—, —NR2—, or —C(═O)—;
• R2 is H, C1-C4alkyl, or C1-C4-fluoroalkyl;
• R3 is H, C1-C4alkyl, C3-C6cycloalkyl, or C1-C4-fluoroalkyl;
• R4 is —NR7C(═O)OCH(R8)—CY, —NR7C(═O)OC(R8)2—CY, or —NR7C(═O)O—CY;
• R7 is H or C1-C4alkyl;
• R8 is H, C1-C4alkyl, or C1-C4-fluoroalkyl;
• CY is C1-C6alkyl, a substituted or unsubstituted C3-C10cycloalkyl, a substituted or unsubstituted C2-C10heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl, wherein if CY is substituted then CY is substituted with 1, 2, or 3 RC;
• or
• R8 and CY are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle;
• each of RA, RB, and RC are independently selected from H, halogen, —CN, —NO2, —OH, —OR10, —SR10, —S(═O)R10, —S(═O)2R10, —N(R9)S(═O)2R10, —S(═O)2N(R9)2, —C(═O)R10, —OC(═O)R10, —CO2R9, —OCO2R10, —N(R9)2, —C(═O)N(R9)2, —OC(═O)N(R9)2, —NR9C(═O)N(R9)2, —NR9C(═O)R10, —NR9C(═O)OR10, C1-C4alkyl, C1-C4-fluoroalkyl, C1-C4-fluoroalkoxy, C1-C4alkoxy, and C1-C4heteroalkyl;
• each R9 is independently selected from H, C1-C6alkyl, C1-C6heteroalkyl, C1-C6-fluoroalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, —C1-C4alkylene-(substituted or unsubstituted cycloalkyl), —C1-C4alkylene-(substituted or unsubstituted heterocycloalkyl), —C1-C4alkylene-(substituted or unsubstituted aryl), or —C1-C4alkylene-(substituted or unsubstituted heteroaryl);
• or
• two R9 groups attached to the same N atom are taken together with the N atom to which they are attached to form a substituted or unsubstituted heterocycle;
• R10 is selected from C1-C6alkyl, C1-C6heteroalkyl, C1-C6-fluoroalkyl, a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, —C1-C4alkylene-substituted or unsubstituted cycloalkyl, —C1-C4alkylene-(substituted or unsubstituted heterocycloalkyl), —C1-C4alkylene-(substituted or unsubstituted aryl), and —C1-C4alkylene-(substituted or unsubstituted heteroaryl).